Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases

Journal of Investigative Dermatology Symposium Proceedings

Volumn 16, Issue 1, 2013, Pages S70-S72

  Gadina, Massimo ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RUXOLITINIB; STAT PROTEIN; TOFACITINIB;

ANIMAL; AUTOIMMUNE DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

MLCS; MLOWN;

EID: 84907227563     PISSN: 10870024     EISSN: 15291774     Source Type: Journal    
DOI: 10.1038/jidsymp.2013.29     Document Type: Review

References (11)

1. Fleischmann, R., Kremer, J., Cush, J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med 367 (2012), 495–507.
2. Ghoreschi, K., Jesson, M.I., Li, X., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186 (2011), 4234–4243.
3. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (2012), 787–798.
4. Karaman, M.W., Herrgard, S., Treiber, D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26 (2008), 127–132.
5. Kralovics, R., Passamonti, F., Buser, A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005), 1779–1790.
6. Leonard, W.J., O'Shea, J.J., Jaks and STATs: biological implications. Annu Rev Immunol 16 (1998), 293–322.
7. Mascarenhas, J., Hoffman, R., Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 18 (2012), 3008–3014.
8. O'Shea, J.J., Gadina, M., Kanno, Y., Cytokine signaling: birth of a pathway. J Immunol 187 (2011), 5475–5478.
9. Strand, V., Kimberly, R., Isaacs, J.D., Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6 (2007), 75–92.
10. van Vollenhoven, R.F., Fleischmann, R., Cohen, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367 (2012), 508–519.
11. Xavier, R.J., Rioux, J.D., Genome-wide association studies: a new window into immune-mediated diseases. Nat Rev Immunol 8 (2008), 631–643.